Clinical trial
A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
NCT02146313 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 22, 2014
- Completion date
- June 18, 2018
- Enrollment
- 35 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.